2017
DOI: 10.1111/1346-8138.14181
|View full text |Cite
|
Sign up to set email alerts
|

Case of Penicillium marneffei infection in a non‐AIDS patient

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 5 publications
(6 reference statements)
0
1
0
Order By: Relevance
“…In recent years, it has been reported that an increasing number and proportion of cases in non-HIV-infected patients who had some form of immunodeficiency (hypogammaglobulinemia, CD4 lymphopenia) or underlying diseases with immunocompromised condition, including hematologic malignancies or autoimmune diseases, were receiving treatments that could impair their cellular immunity, such as antineoplastic or corticosteroid agents [ 8 , 9 ]. However, some researchers have recommended that T. marneffei infection also occur in persons with normal immunity [ 4 , 8 , 10 12 ]. Here, we report an unusual case of disseminated T. marneffei infection in non-HIV, non-immunosuppressed and non-endemic conditions.…”
Section: Introductionmentioning
confidence: 99%
“…In recent years, it has been reported that an increasing number and proportion of cases in non-HIV-infected patients who had some form of immunodeficiency (hypogammaglobulinemia, CD4 lymphopenia) or underlying diseases with immunocompromised condition, including hematologic malignancies or autoimmune diseases, were receiving treatments that could impair their cellular immunity, such as antineoplastic or corticosteroid agents [ 8 , 9 ]. However, some researchers have recommended that T. marneffei infection also occur in persons with normal immunity [ 4 , 8 , 10 12 ]. Here, we report an unusual case of disseminated T. marneffei infection in non-HIV, non-immunosuppressed and non-endemic conditions.…”
Section: Introductionmentioning
confidence: 99%